Frequency of MART-1/MelanA and gp100/PMel17-Specific T Cells in Tumor Metastases and Cultured Tumor-Infiltrating Lymphocytes

Journal of Immunotherapy

Volumn 25, Issue 3, 2002, Pages 252-263

  Seiter, Simone ^a   Monsurro, Vladia ^a   Nielsen, Mai Britt ^a   Wang, Ena ^a   Provenzano, Maurizio ^a   Wunderlich, John R ^a   Rosenberg, Steven A ^a   Marincola, Francesco M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Immunotherapy; Melanoma antigens; Tumor specific antigens

Indexed keywords

GLYCOPROTEIN GP 100; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MELANOMA ANTIGEN; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE CULTURE; MELANOMA; METASTASIS; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, NEOPLASM; HEMATOPOIETIC STEM CELLS; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PROTEINS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0036096282     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200205000-00008     Document Type: Article

References (43)

1. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas [see comments]. J Exp Med 1994; 180:35-42.
2. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 91:3515-9.
3. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91:6458-62.
4. Stevens EJ, Jacknin L, Robbins PF, et al. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. J Immunol 1995; 154:762-71.
5. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988; 319:1676-80.
6. Marincola FM, Rivoltini L, Salgaller ML, et al. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence for in vivo priming by tumor cells. J Immunother 1996; 19:266-77.
7. D'Souza S, Rimoldi D, Lienard D, et al. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. Int J Cancer 1998; 78:699-706.
8. Loftus DJ, Castelli C, Clay TM, et al. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J Exp Med 1996; 184:647-57.
9. Kim CJ, Parkinson DR, Marincola FM. Immunodominance across the HLA polymorphism: implications for cancer immunotherapy. J Immunother 1997; 21:1-16.
10. Rosenberg SA, Yang JC, Schwartzentruber D, et al. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321-7.
11. Kawakami Y, Dang N, Wang X, et al. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating lymphocytes from 123 patients with melanoma. J Immunother 2000; 23:17-27.
12. Anichini A, Molla A, Mortarini R, et al. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 1999; 190:651-67.
13. Schmittel A, Keilholz U, Scheibenbogen C. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J Immunol Methods 1997; 210:167-74.
14. Gajewski TF. Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers and beyond. Clin Diag Lab Immunol 2000; 7:141-4.
15. + T cells specific for EBV in healthy virus carriers. J Immunol 1999; 162:1827-35.
16. Dutton RW, Bradley LM, Swain SL. T cell memory. Annu Rev Immunol 1998; 16:201-23.
17. Altman JD, Moss PH, Goulder PR, et al. Phenotypic analysis of antigen-specific T lymphocytes [published erratum appears in Science 1998;280:1821]. Science 1996; 274:94-6.
18. + T cells. J Immunol 2000; 165:2287-96.
19. Ogg GS, Rod DP, Romero P, et al. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998; 188:1203-8.
20. Romero P, Dunbar PR, Valmori D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998; 188:1641-50.
21. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5:677-85.
22. Lee K-H, Wang E, Nielsen M-B, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999; 163:6292-6300.
23. Rivoltini L, Baracchini KC, Viggiano V, et al. Quantitative correlation between HLA Class I allele expression and recognition of melanoma cells by antigen specific cytotoxic T lymphocytes. Cancer Res 1995; 55:3149-57.
24. Wang Z, Marincola FM, Rivoltini L, et al. Selective human leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. J Exp Med 1999; 190:205-15.
25. Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides [see comments]. Nature 1992; 356:443-6.
26. Lee K-H, Panelli MC, Kim CJ, et al. Functional dissociation between local and systemic immune response after peptide vaccination. J Immunol 1998; 161:4183-94.
27. Bunce M, O'Neill CM, Barnardo MC, et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5, and DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995; 46:355-67.
28. Player MA, Barracchini KC, Simonis TB, et al. Differences in frequency distribution of HLA-A2 subtypes between American and Italian Caucasian melanoma patients: relevance for epitope specific vaccination protocols. J Immunother 1996; 19:357-63.
29. Yannelli JR, Hyatt C, McConnell S, et al. Groowth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int J Cancer 1996; 65:413-21.
30. Marincola FM, Hijazi YM, Fetsch P, et al. Analysis of expression of the melanoma associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother 1996; 19:192-205.
31. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995; 154:3961-8.
32. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996; 8:271-80.
33. Ochsenbein AF, Klenerman P, Karrer U, et al. Immune surveillance against a solid tumor fails because of immunologic ignorance. Proc Natl Acad Sci USA 1999; 96:2233-8.
34. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A [see comments]. Cancer J Sci Am 1997; 3:37-44.
35. Sercarz EE, Lehmann PV, Ametani A, et al. Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 1993; 11:729-66.
36. Niedermann G, Butz S, Ihlenfeldt HG, et al. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity 1995; 2:289-99.
37. Cormier JN, Hijazi YM, Abati A, et al. Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998; 75:517-24.
38. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995; 154:2257-65.
39. Balch CM, Itoh K, Tilden AB. Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factor. Surgery 1985; 98:151-7.
40. Bettinotti M, Kim CJ, Lee K-H, et al. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy. J Immunol 1998; 161:877-89.
41. + T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999; 190:705-15.
42. Salgaller ML, Marincola FM, Cormier JN, et al. Immunization against epitopes in the human melanoma antigen gp100 after patient immunization with synthetic peptides. Cancer Res 1996; 56:4749-57.
43. el-Shami K, Tirosh B, Bar-Haim E, et al. MHC class I-restricted epitope spreading in the context of tumor rejection after vaccination with a single immunodominant epitope. Eur J Immunol 1999; 29:3295-3301.